Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension

Clinical and Experimental Hypertension

Volumn 28, Issue 5, 2006, Pages 451-461

  Watanabe, Sanae ^a   Okura, Takafumi ^a   Kurata, Mie ^a   Irita, Jun ^a   Manabe, Seiko ^a   Miyoshi, Ken Ichi ^a   Fukuoka, Tomikazu ^a   Gotoh, Akiko ^b   Uchida, Kazuo ^b   Higaki, Jitsuo ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kyoto Medical Science Laboratory   (Japan)

Author keywords

Cystatin C; Hypertension; Microalbuminuria; Renal hemodynamics; Valsartan

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CREATININE; CYSTATIN C; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIASTOLIC BLOOD PRESSURE; DOPPLER FLOWMETER; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; KIDNEY ARTERY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PULSATILE FLOW; RESISTANCE BLOOD VESSEL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CREATININE; CYSTATIN C; CYSTATINS; FEMALE; HUMANS; HYPERTENSION; JAPAN; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSATILE FLOW; RENAL CIRCULATION; TETRAZOLES; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER; VALINE; VASCULAR RESISTANCE;

EID: 33745841572     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960600798671     Document Type: Article

References (40)

1. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet 1988; 2:530-533.
2. Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. Br Med J 1990; 300:297-300.
3. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion - a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996; 9:770-788.
4. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47:312-318.
5. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (γ-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 1985; 45:97-101.
6. Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and β2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985; 218:499-503.
7. Tian S, Kusano E, Ohara T, Tabei K, Itoh Y, Kawai T, Asano Y. Cystatin C measurement and its practical use in patients with various renal diseases. Clin Nephrol 1997; 48:104-108.
8. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004; 110:2342-2348.
9. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005; 51:321-327.
10. Watanabe S, Okura T, Liu J, Miyoshi K, Fukuoka T, Hiwada K, Higaki J. Serum cystatin C level is a marker of end-organ damage in patients with essential hypertension. Hypertens Res 2003; 26:895-899.
11. Avasthi PS, Voyles WF, Greene ER. Noninvasive diagnosis of renal artery stenosis by echoDoppler velocimetry. Kidney Int 1984; 25:824-829.
12. Deyoe LA, Cronan JJ, Breslaw BH, Ridlen MS. New techniques of ultrasound and color Doppler in the prospective evaluation of acute renal obstruction. Abdom Imaging 1995; 20:58-63.
13. Stevens PE, Gwyther SJ, Hanson ME, Woodrow DF, Phillips ME, Boultbee JE. Interpretation of duplex Doppler ultrasound in renal transplants in the early postoperative period. Nephrol Dial Transplant 1993; 8:255-258.
14. Petersen LJ, Petersen JR, Ladefoged SD, Mehlsen J, Jensen HA. The pulsatility index and the resistive index in renal arteries in patients with hypertension and chronic renal failure. Nephrol Dial Transplant 1995; 10:2060-2064.
15. Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V, Leoncini G. Ruello N, Zagami P, Bezante GP, Derchi LE, Deferrari G. Increased renal resistive index in patients with essential hypertension: a marker of target organ damage. Nephrol Dial Transplant 1999; 14:360-365.
16. Boeri D, Derchi LE, Martinoli C, Simoni G, Sampietro L, Storace D, Ponte L, Calvi C, Repetto M, Robaudo C, Maiello M. Intrarenal arteriosclerosis and impairment of kidney function in NIDDM subjects. Diabetologia 1998; 41:121-124.
17. Iino Y, Hayashi M, Kawamura T, Shiigai T, Tomino Y, Yamada K, Kitajima T, Ideura T, Koyama A, Sugisaki T, Suzuki H, Umemura S, Kawaguchi Y, Uchida S, Kuwahara M, Yamazaki T. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study. Clin Exp Nephrol 2003; 7:221-230.
18. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
19. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
20. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:117-124.
21. Uchida K, Gotoh A. Measurement of cystatin-C and creatinine in urine. Clinica Chimica Acta 2002; 323:121-128.
22. Okura T, Watanabe S, Miyoshi K, Fukuoka T, Higaki J. Intrarenal and carotid hemodynamics in patients with essential hypertension. Am J Hypertens 2004; 17:240-244.
23. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in the hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12:218-225.
24. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-2169.
25. Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrom V, Grubb A. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40:1921-1926.
26. Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A. Structure and expression of the human cystatin C gene. Biochem J 1990; 268:287-294.
27. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357:1601-1608.
28. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
29. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T, Remuzzi G. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4:40-49.
30. Morelli E, Loon N, Meyer T, Peters W, Myers BD. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39:76-82.
31. Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000; 58:2129-2137.
32. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, Campistol JM. Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001; 16:90-93.
33. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44:874-877.
34. Gosling RG, Dunbar G, King DH, Newman DL, Side CD, Woodcock JP, Fitzgerald DE, Keates JS, MacMillan D. The quantitative analysis of occlusive peripheral arterial disease by a non-intrusive ultrasonic technique. Angiology 1971; 22:52-55.
35. Pourecet L. Applications clinique de l'examen Doppler transcutane. In: Peronneau P, ed. Symposium: Velocimetric Ultrasonnor-doppler. Paris: Inserm; 1974, pp. 213-240.
36. Losito A, Zampi I, Fortunati I, del Favero A. Glomerular hyperfiltration and albuminuria in essential hypertension. Nephron 1988; 49:84-85.
37. Rosa TT, Palatini P. Clinical value of microalbuminuria in hypertension. J Hypertens 2000; 18:645-654.
38. Leoncini G, Martinoli C, Viazzi F, Ravera M, Parodi D, Ratto E, Vettoretti S, Tomolillo C, Derchi LE, Deferrari G, Pontremoli R. Changes in renal resistive index and urinary albumin excretion in hypertensive patients under long-term treatment with lisinopril or nifedipine GITS. Nephron 2002; 90:169-173.
39. Caruso D, D'Avino M, Acampora C, Romano L, Bevilacqua N, Caruso G, Esposti DD, Borghi C. Effects of losartan and chlorthalidone on blood pressure and renal vascular resistance index in non-diabetic patients with essential hypertension and normal renal function. J Cardiovasc Pharmacol 2004; 44:520-524.
40. Rowe DJ, Dawnay A, Watts GF. Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 1990; 27:297-312.